Active films were prepared from chitosan (Ch) and polyvinyl alcohol (PVA) containing aqueous mint extract (ME)/pomegranate peel extract (PE). The effect of these extracts on the physical, mechanical, ...antimicrobial and antioxidant properties of the films were studied. Increased protection against UV light was observed in the films containing the extracts. Addition of ME/PE improved the tensile strength of the films without affecting their puncture strength. Ch–PVA films incorporated with PE had the highest tensile strength (41.07 ± 0.88 MPa). Permeability characteristics of the films were not altered due to addition of extracts. ME/PE conferred antioxidant properties to Ch–PVA films as determined by DPPH radical scavenging activity. The films also exhibited antibacterial activity against Staphylococcus aureus and Bacillus cereus. PE containing films totally inhibited the growth of B. cereus and reduced the number of S. aureus by 2 log cycles. These results suggest that Ch–PVA film containing ME/PE can be used for development of active food packaging materials.
Display omitted
► Active chitosan–PVA films were developed. ► Mint extract/pomegranate peel extract used as active ingredient. ► Films had improved tensile strength and permeability was not altered. ► The natural extracts conferred antioxidant properties to the film. ► Films exhibited antibacterial activity against S. aureus and B. cereus.
Abstract
We report on the discovery of FRB 20200120E, a repeating fast radio burst (FRB) with a low dispersion measure (DM) detected by the Canadian Hydrogen Intensity Mapping Experiment FRB project. ...The source DM of 87.82 pc cm
−3
is the lowest recorded from an FRB to date, yet it is significantly higher than the maximum expected from the Milky Way interstellar medium in this direction (∼50 pc cm
−3
). We have detected three bursts and one candidate burst from the source over the period 2020 January–November. The baseband voltage data for the event on 2020 January 20 enabled a sky localization of the source to within ≃14 arcmin
2
(90% confidence). The FRB localization is close to M81, a spiral galaxy at a distance of 3.6 Mpc. The FRB appears on the outskirts of M81 (projected offset ∼20 kpc) but well inside its extended H
i
and thick disks. We empirically estimate the probability of a chance coincidence with M81 to be <10
−2
. However, we cannot reject a Milky Way halo origin for the FRB. Within the FRB localization region, we find several interesting cataloged M81 sources and a radio point source detected in the Very Large Array Sky Survey. We search for prompt X-ray counterparts in Swift Burst Alert Telescope and Fermi/GBM data, and, for two of the FRB 20200120E bursts, we rule out coincident SGR 1806−20-like X-ray bursts. Due to the proximity of FRB 20200120E, future follow-up for prompt multiwavelength counterparts and subarcsecond localization could be constraining of proposed FRB models.
Abstract Background Giant-cell tumours of bone (GCTB) are RANK/RANK-ligand (RANKL) positive, aggressive and progressive osteolytic tumours. Denosumab, a RANKL inhibitor, was FDA-approved for adults ...and skeletally mature adolescents with unresectable GCTB or when surgical resection is likely to result in severe morbidity. Data on long-term toxicity and activity of denosumab monthly ‘GCTB-schedule’ (120 mg per 12/year, 1440 mg total dose/year) are lacking. Methods Patients with GCTB receiving denosumab, 120 mg on days 1, 8, 15, 29 and every 4 weeks thereafter, from 2006 to 2015 treated in two centres were included. Long-term toxicity was evaluated. Results Ninety-seven were identified. 43 patients underwent resection of the tumour with a median time on denosumab treatment of 12 months (range 6–45 months). Fifty-four patients had unresectable GCTB's (male/female 23/31, median age 35 years range: 13–76 years, 26% presented with lung metastases, 31% had primary tumor located to the spine, 63% were relapsed after previous surgery) with a median time on denosumab of 54 months (9–115 months). In the unresectable GCTB group, tumour control and clinical benefits were observed in all patients undergoing denosumab, whereas 40% of patients discontinuing denosumab had tumour progression after a median of 8 months (range 7–15 months). Adverse events Overall, six (6%) patients developed osteonecrosis of jaw (ONJ): 1/43 (2%) in the resectable group, 5/54 (9%) in the unresectable group, with a 5-year ONJ-free survival of 92% (95% CI 84–100). Only patients with prolonged treatment experienced mild peripheral neuropathy (6/54, 11%), skin rash (5/54, 9%), hypophosphataemia (2/54, 4%) and atypical femoral fracture (2/54, 4%). Conclusions Prolonged treatment with denosumab has sustained activity in GCTB, with a mild toxicity profile. The dose-dependent toxicity observed recommends a careful and strict monitoring of patients who need prolonged treatment. Decreased dose-intensity schedules should be further explored in unresectable GCTB.
Cervical cancer is a major health problem and a leading cause of death among women in India. Of all the associated risk factors, high-risk human papillomavirus (HPV) infections being the principal ...aetiologic agent, two HPV vaccines are in use for the control of cervical cancer. The present study was undertaken to explore the knowledge, attitude and practice (KAP) on HPV vaccination among the healthcare providers in India.
A cross-sectional study was conducted among 590 healthcare professionals from 232 hospitals and 80 PHCs of nine districts of Delhi-NCR (National Capital Region). A total of 590 (526 female, 64 male) healthcare providers were surveyed.
Only 47 per cent of respondents recommended young women to get vaccinated against HPV. Majority of respondents (81%) were found to be aware about the existence of vaccines for cervical cancer prevention. District-wise, highest (88.3%) awareness about the existence of vaccines against HPV was reported from Gautam Budh Nagar and lowest (64%) in Faridabad. Although 86 per cent of gynaecologists were aware about the names of HPV vaccines available in the market, only 27 per cent of paramedical staff had this knowledge. There was a significant difference between the respondents from government and private sectors regarding their awareness about HPV vaccines. Lack of awareness about the principal cause, risk factors and symptoms for cervical cancer and HPV vaccination was significantly (P< 0.05) reported in the respondents from paramedical staff category.
The findings reinforce continued medical education of healthcare providers, particularly those from the government sector on HPV vaccination for cervical cancer prevention. Public education is also pertinent for a successful HPV vaccination programme in the country.
Trabectedin (ET743, Yondelis
®
, manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian,
Ecteinascidia turbinata
, is ...a natural alkaloid with multiple complex mechanisms of action. On 23 October 2015, 15 years after the results of the first Phase 1 clinical trial using trabectedin for chemotherapy-resistant solid malignancies was reported, and 8 years after its approval in Europe, the United States Food and Drug Administration (USFDA) finally approved trabectedin for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma that has failed a prior anthracycline-containing regimen. Approval was based on the results of a pivotal Phase 3 trial involving a 2:1 randomization of 518 patients (who were further stratified by soft tissue sarcoma subtype), in which a significant improvement in progression-free survival was reported in the trabectedin-treated group vs. the dacarbazine-treated group (
p
< 0.001). In this trial, the most common adverse reactions were nausea, fatigue, vomiting, constipation, anorexia, diarrhea, peripheral edema, dyspnea, and headache, while the most serious were neutropenic sepsis, rhabdomyolysis, cardiomyopathy, hepatotoxicity, and extravasation leading to tissue necrosis. The most common grade 3–4 adverse events were laboratory abnormalities of myelosuppression in both arms and transient transaminitis in the trabectedin arm. In a recent Phase 2 trial, trabectedin had a similar outcome as doxorubicin when given as a single agent in the first-line setting. Studies are also being conducted to expand the use of trabectedin not only as a first-line cancer drug, but also for a number of other clinical indications, for example, in the case of mesenchymal chondrosarcoma, for which trabectedin has been reported to be exceptionally active. The possibility of combining trabectedin with targeted therapies, immune checkpoint inhibitors or virotherapy would also be an interesting concept. In short, trabectedin is an old new drug with proven potential to impact the lives of patients with soft tissue sarcoma and other solid malignancies.
Funding
: Sarcoma Oncology Center, Santa Monica, CA 90405.
We report on the discovery and analysis of bursts from nine new repeating fast radio burst (FRB) sources found using the Canadian Hydrogen Intensity Mapping Experiment (CHIME) telescope. These ...sources span a dispersion measure (DM) range of 195-1380 pc cm−3. We detect two bursts from three of the new sources, three bursts from four of the new sources, four bursts from one new source, and five bursts from one new source. We determine sky coordinates of all sources with uncertainties of ∼10′. We detect Faraday rotation measures (RMs) for two sources, with values −20(1) and −499.8(7) rad m−2, that are substantially lower than the RM derived from bursts emitted by FRB 121102. We find that the DM distribution of our events, combined with the nine other repeaters discovered by CHIME/FRB, is indistinguishable from that of thus far non-repeating CHIME/FRB events. However, as previously reported, the burst widths appear statistically significantly larger than the thus far non-repeating CHIME/FRB events, further supporting the notion of inherently different emission mechanisms and/or local environments. These results are consistent with previous work, though are now derived from 18 repeating sources discovered by CHIME/FRB during its first year of operation. We identify candidate galaxies that may contain FRB 190303.J1353+48 (DM = 222.4 pc cm−3).
The Canadian Hydrogen Intensity Mapping Experiment (CHIME) is a novel transit radio telescope operating across the 400-800 MHz band. CHIME is composed of four 20 m × 100 m semicylindrical paraboloid ...reflectors, each of which has 256 dual-polarization feeds suspended along its axis, giving it a 200 deg2 field of view. This, combined with wide bandwidth, high sensitivity, and a powerful correlator, makes CHIME an excellent instrument for the detection of fast radio bursts (FRBs). The CHIME Fast Radio Burst Project (CHIME/FRB) will search beam-formed, high time and frequency resolution data in real time for FRBs in the CHIME field of view. Here we describe the CHIME/FRB back end, including the real-time FRB search and detection software pipeline, as well as the planned offline analyses. We estimate a CHIME/FRB detection rate of 2-42 FRBs sky-1 day-1 normalizing to the rate estimated at 1.4 GHz by Vander Wiel et al. Likely science outcomes of CHIME/FRB are also discussed. CHIME/FRB is currently operational in a commissioning phase, with science operations expected to commence in the latter half of 2018.
Discusses the role of denosumab, a monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), in modifying the pathogenesis of giant-cell tumor of bone (GCTB), and the ...evolving management of GCTB with the introduction of denosumab. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.
We report on the discovery of eight repeating fast radio burst (FRB) sources found using the Canadian Hydrogen Intensity Mapping Experiment (CHIME) telescope. These sources span a dispersion measure ...(DM) range of 103.5-1281 pc cm−3. They display varying degrees of activity: six sources were detected twice, another three times, and one 10 times. These eight repeating FRBs likely represent the bright and/or high-rate end of a distribution of infrequently repeating sources. For all sources, we determine sky coordinates with uncertainties of ∼10′. FRB 180916.J0158+65 has a burst-averaged DM = 349.2 0.3 pc cm−3 and a low DM excess over the modeled Galactic maximum (as low as ∼20 pc cm−3); this source also has a Faraday rotation measure (RM) of −114.6 0.6 rad m−2, which is much lower than the RM measured for FRB 121102. FRB 181030.J1054+73 has the lowest DM for a repeater, 103.5 0.3 pc cm−3, with a DM excess of ∼70 pc cm−3. Both sources are interesting targets for multi-wavelength follow-up due to their apparent proximity. The DM distribution of our repeater sample is statistically indistinguishable from that of the first 12 CHIME/FRB sources that have not yet repeated. We find, with 4 significance, that repeater bursts are generally wider than those of CHIME/FRB bursts that have not repeated, suggesting different emission mechanisms. Many of our repeater events show complex morphologies that are reminiscent of the first two discovered repeating FRBs. The repetitive behavior of these sources will enable interferometric localizations and subsequent host galaxy identifications.
PDF
